REBIRTH funding continued
Great success for the Hannover Medical School (MHH): On June 15th the German Research Foundation (DFG) and the German Council of Science and Humanities (Wissenschaftsrat, WR) announced further funding of the Cluster of Excellence REBIRTH (from Regenerative Biology to Reconstructive Therapy). Funding has been granted for another five years with up to eight millions per year.
With the Cluster of Excellence, outstanding research at German Universities is funded by Germany’s federal and state governments. Clusters of Excellence are, together with graduate schools and institutional strategies, the three funding lines of the Excellence Initiative. At the press conference the president of the DFG, Prof. Kleiner, complimented all applicants, saying: “The competition was intense and top-class. The evaluators were very impressed by the quality of most of the applications – and so was the Grants Committee”.
Prof. Axel Haverich, as well as Prof. Christopher Baum and Prof. Ulrich Martin coordinate the Cluster of Excellence REBIRTH. A high degree of interdisciplinary collaboration, including chemistry, physics, and engineering science, is the basis of REBIRTH research. Therefore, scientists from the MHH, the Leibniz University Hannover, the University of Veterinary Medicine Hannover (TiHo), the Fraunhofer Institute for Toxicology and Experimental Medicine, the Institute of Farm Animal Genetics in Mariensee, the Helmholtz Centre for Infection Research in Braunschweig, the Laser Zentrum Hannover, and the Max Planck Institute for Molecular Biomedicine in Münster are cooperating in this Cluster of Excellence. Additionally, a wide range of research, from fundamentals to clinical applications, is characteristic for REBIRTH. Scientists involved in REBIRTH are focusing on the development of regenerative therapies of blood, heart, liver, and lung.
As one of the central research areas of the Cluster of Excellence REBIRTH, the LEBAO focuses mainly on the development of new therapies for cardiovascular and respiratory diseases, and especially on induced pluripotent stem cells, tissue engineering, and the development of biohybrid implants and organs.
The REBIRTH speaker, Prof. Axel Haverich, said: “The continued funding proves our excellent research and allows us to further improve our competence, especially for the patients good”.
Please find further information here: